BMJ Learning: Myeloma: Practical tips for primary care
In collaboration with BMJ Learning, we have created a new course for GPs on myeloma. This interactive course gives practical tips on the detection and diagnosis of myeloma and MGUS.
DetailsIn collaboration with BMJ Learning, we have created a new course for GPs on myeloma. This interactive course gives practical tips on the detection and diagnosis of myeloma and MGUS.
DetailsWe have partnered with GatewayC on their updated Myeloma Early Diagnosis course, available for all primary care professionals.
This course aims to increase GPs’ awareness of patients with suspected myeloma and support them to undertake the appropriate investigations and understand how to interpret the results.
DetailsIn June, the first results from the OPTIMUM/MUK nine clinical trial were presented at international conferences.
The trial is the first to use state-of-the-art diagnostics and genetic profiling to screen for patients with high-risk myeloma.
These results show that treatment with a five-drug induction treatment (Dara-CVRd) and stem cell transplant is effective and well tolerated in ultra-high risk myeloma patient
Throughout 2021, the Patient Advocacy Team have been continuing their work to support patient access to new treatments on the NHS. Read more about the four active Health Technology Appraisals including the first-ever appraisal for an AL amyloidosis treatment.
DetailsFind out more about the educational resources our Clinical Practice Services Team have been developing to raise HCP awareness of myeloma.
DetailsThe Clinical Trials Research Unit at the University of Leeds has produced a series of webinars for researchers and clinicians about the UK Myeloma Research Alliance (UKMRA)-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma clinical trials in the UK.
DetailsThese new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Forum, provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
This important virtual national conference provides an essential update for current and aspiring non medical prescribers on prescribing at the end of life. It is widely recognized that pain and symptom control at the end of life is not always optimal, the development of non medical prescribing has a key role in improving pain and…
DetailsNew treatments for myeloma continue to come through the appraisal pipeline. In the last few months, there have been several new treatment approvals from both the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC), which is excellent news for patients. Hopefully, there will be more good news for patients throughout 2021…
Details